We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Promising Blood Biomarkers Isolated for Colorectal Cancer

By LabMedica International staff writers
Posted on 12 Nov 2014
Print article
Histopathology of colonic adenocarcinoma; the glands are enlarged and filled with necrotic debris (Photo courtesy of the University of Utah).
Histopathology of colonic adenocarcinoma; the glands are enlarged and filled with necrotic debris (Photo courtesy of the University of Utah).
The search for blood-borne biomarkers that could be used to screen for colorectal cancer (CRC) has uncovered two promising candidates that may one day lead to the development of a simple blood test.

Screening for CRC is both effective and cost-effective in the average-risk population, with the two recommended strategies being stool tests that identify occult blood or exfoliated DNA associated with cancer, and structural examinations such as colonoscopy that detect both cancer and premalignant lesions.

Scientist from the Institute of Digestive Diseases Hospital Clinic (Barcelona, Spain) have been piecing together the molecular events involved in the development of CRC and have identified abnormal DNA methylation patterns and the presence of micro ribonucleic acids (miRNAs) as major players in the carcinogenic process. Cancer biomarkers are biological changes that signal the presence of cancer in the body and are usually related to alterations in DNA, RNA, or protein expression. Investigations have revealed that tumor-derived DNA in the blood have observed abnormal DNA methylation patterns, specifically, abnormally methylated Septin-9 (SEPT9) DNA, in the patients with CRC, suggesting a potential new DNA-based biomarker for screening.

The second potential screening approach involves assessing the profile of small, non-coding RNAs, known as miRNAs, which have been shown to be increased in the plasma from patients with CRC. The scientists found that patients with CRC or advanced adenomas had a significantly different pattern of miRNA expression compared with healthy individuals, leading the group to conclude that plasma miRNA testing was a promising screening test for CRC that warrants further investigation.

Antoni Castells Garangou, MD, the lead investigator in the study, said, “Both of these potential new CRC screening approaches have shown promise in preliminary studies and should be explored further in larger cohorts of patients. There is no doubt in my mind that having an accurate, blood-based screening method would increase adherence to CRC screening guidelines and reduce the number of patients reluctant to be screened.” The study was presented on October 22, 2104, at the 22nd United European Gastroenterology Week held in Vienna (Austria).

Related Links:

Institute of Digestive Diseases Hospital Clinic 


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Real-time PCR System
GentierX3 Series

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.